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Pulmonary Metastasectomy
A Survey of Current Practice Amongst Members of the European
Society of Thoracic Surgeons
Eveline Internullo, MD,* Stephen D. Cassivi, MD, MSc, FRCSC,† Dirk Van Raemdonck, MD, PhD, FETCS,*
Godehard Friedel, MD, PhD,‡ and Tom Treasure, MD, MS, FRCS,§ on behalf of the ESTS Pulmonary
Metastasectomy Working Groupa
Objective: Currently, no randomized trials exist to guide thoracic
surgeons in the field of pulmonary metastasectomy. This study
investigates the current clinical practice among European Society of
Thoracic Surgeon (ESTS) members.
Methods: A Web-based questionnaire was created exploring the
clinical approach to lung metastasectomy. All ESTS members were
surveyed.
Results: One hundred forty-six complete responses were received
from the 494 consultant ESTS members surveyed (29.6%). For most
respondents (68%), lung metastasectomy represents a minor propor-
tion (0–10%) of their clinical volume. Approximately 90% of
respondents always/usually review their lung metastasectomy cases
within a multidisciplinary meeting. Helical computed tomography is
most commonly used (74%) for the detection of metastases, while
positron emission tomography is used additionally in less than 50%.
Most of respondents (92% and 74%, respectively) consider unre-
sectable primary tumor and predicted incomplete metastasectomy as
absolute contraindications to lung metastasectomy. The most fre-
quently performed resection is wedge excision (92%). Palpation of
the lung is considered necessary by 65%, while 40% use a thoraco-
scopic approach with therapeutic intent. Though 65% consider
pathologically positive nodes a contraindication to metastasectomy,
a similar number rarely/never perform mediastinoscopy before me-
tastasectomy. At the time of metastasectomy 55% perform medias-
tinal lymph node sampling whereas 33% perform no nodal dissec-
tion whatsoever.
Conclusions: The survey provides a large, time-sensitive database
summarizing the clinical practice of pulmonary metastasectomy by
members of the ESTS. Responses demonstrate a remarkable consis-
tency of practice patterns, though certain areas of potential contro-
versy showed greater variance. Conceivably, these divergent ap-
proaches will encourage future collaborative studies aimed at
identifying evidence-based practices for patients with pulmonary
metastases.
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Surgical resection is widely employed as a conventionaltreatment option for patients with lung metastases origi-
nating from a wide range of primary tumors. There is to date,
however, no higher level of evidence than case series and
metastasectomy registries to support the many aspects of this
form of treatment.1 From the fundamentals of basic patient
selection, to the chosen surgical approach, there is no pre-
vailing evidence that guides practice. The heterogeneity in
the biologic behavior of the many primary tumors adds to the
difficulty in drawing conclusions from mixed series. The very
essence of the practice, that is a belief that pulmonary
metastasectomy can prolong survival, has been questioned.1–3
With such a paucity of evidence in support of clear practice
guidelines, and the potential for significant practice variation,
the European Society of Thoracic Surgeons (ESTS) Pulmo-
nary Metastasectomy Working Group (PMWG) decided to
survey ESTS members in an effort to define the current
practice of pulmonary metastasectomy.
MATERIALS AND METHODS
A Web-based questionnaire was designed by a sub-
group of the PMWG and all ESTS members were invited
to respond from November 2006 through January 2007
using a commercially available, online survey designer
(www.surveymonkey.com). During this 3-month period
three reminders were sent to the ESTS members to boost
responses. The questionnaire consisted of 39 questions,
subdivided in 7 sections, exploring the various aspects of
lung metastasectomy: indications and contraindications,
role of chemotherapy, preoperative diagnosis, role of me-
diastinal node assessment, extent of resection, surgical
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approach (open versus thoracoscopic, sequential bilateral
procedures versus median sternotomy, etc.) and technique
(anatomic versus nonanatomic resection, stapled wedge
resection versus laser enucleation, etc.), the role of palpa-
tion of the lungs, and follow-up strategies (Appendix).
Demographic data from the responders were collected
(type of practice, age, years in practice, unit size, country of
practice).
The questionnaire was pretested on the members of the
PMWG (n  24) to identify errors in question formulation
and clarity. No major change was required prior to release of
the questionnaire to the membership at-large.
Only completely answered questionnaires by full-mem-
bers of the ESTS (consultants) were considered for analysis
(i.e., trainee responses were not included in this analysis).
Data are presented in both numbers and percentages.
Percentages are rounded to one decimal place.
RESULTS
Response
At the time the survey was administered, the ESTS had
494 full-members and 149 trainees. E-mail delivery of the
survey was successful in 576 cases. By the closure of the
survey, 200 responses had been collected. Of these, 39 were
incomplete and were excluded from further analysis. Among
the remaining 161, 15 were from trainees, thus also elimi-
nated. One hundred forty-six completed questionnaires by
consultant ESTS members are the object of the analysis of
this study (Figure 1). These completed surveys reflect the
practice of 29.6% of the ESTS full-members from 29 coun-
tries (Table 1). The responses of the members of the Working
Group are included in the 146 completed surveys analyzed
for this study.
Responders
The mean age of the responders was 46.6 years (range,
33–67). Eighty-eight (60.3%) of the responders work in a
Unit of more than 20 beds. Eighty-two (56.2%) work in
academic hospitals, 60 (41.1%) in public hospitals, and 4
(2.7%) in private hospitals.
All the responders perform lung metastasectomy in
their clinical practice. The number of lung metastasectomy
cases per year varies widely (median 17, range 2–150), but
for most of the surveyed surgeons, metastasectomy represents
a minor proportion of their clinical volume: 0 to 10% for
68.8% (99/144) and 10 to 25% for 28.5% (41/144). This
datum does not seem to differ according to age of the
surgeon, thoracic unit size or academic/public practice.
Preoperative Work Up
Among reported ESTS thoracic surgeons 52.1% de-
clared that they review all candidates for pulmonary metas-
tasectomy cases in a multidisciplinary meeting. Another 39%
did so usually while 2.7% never discuss such cases within a
multidisciplinary team. Reported rates were similar for aca-
demic and public hospital practices.
FIGURE 1. Calculation of the response rate of the survey.
TABLE 1. Geographic Distribution of the Responses
Country No. of Responses (%)
Italy 23 (15.8)
Germany 14 (10.0)
Spain 11 (7.5)
The Netherlands 10 (6.8)
Greece 9 (6.2)
United Kingdom 9 (6.2)
Switzerland 7 (4.8)
Turkey 7 (4.8)
Austria 6 (4.1)
Belgium 5 (3.4)
France 5 (3.4)
Poland 5 (3.4)
USA 5 (3.4)
Denmark 4 (2.7)
Romania 4 (2.7)
Serbia 3 (2.1)
Croatia 2 (1.4)
Hungary 2 (1.4)
Portugal 2 (1.4)
Canada 1 0.7
Cyprus 1 0.7
Czech Republic 1 0.7
Estonia 1 0.7
India 1 0.7
Israel 1 0.7
Luxembourg 1 0.7
Saudi Arabia 1 0.7
Slovenia 1 0.7
Sweden 1 0.7
Total responders 143 97.9
Unknown country (skipped question) 3 2.1
Internullo et al. Journal of Thoracic Oncology • Volume 3, Number 11, November 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1258
All the responding surgeons use computed tomography
(CT) scan (49% conventional CT, 51% helical CT scan) as
the main imaging modality to diagnose and plan for pulmo-
nary metastasectomy. The choice between standard or helical
CT scan is likely to be dictated by local availability rather
than by personal preference. The use of positron emission
tomography (PET) in the preoperative assessment of lung
metastasectomy is less common: 44.5% always/usually use it,
29.5% sometimes, 26% rarely/never.
Serum tumor markers, depending on the histology of
the primary tumor, are measured systematically by 33.6% of
the responders, another 30.8% usually check them.
Primary Tumor Histology
In most cases, the primary tumor cell type was not
stated to be a limitation/contraindication to lung metastasec-
tomy by those responding (Table 2). This remained true for
cancers known to have a poor prognosis such as melanoma.
The lowest rates were for gynaecological cancers but still
about two thirds of surgeons reported resecting these. Pul-
monary metastasectomy for a lung cancer primary was re-
ported to be performed by 69% of the responders.
Indications/Contraindications
Multiple pulmonary metastases, bilateral or recurrent
pulmonary metastases are not considered per se contraindi-
cations to resection by 84.9%, 82.2%, and 74.7% of the
responders respectively. Synchronous lung metastases, mean-
ing those found at the time of diagnosis of the primary tumor
(disease free interval  0) are not a contraindication for 50%
of responders, and a relative contraindication for 47% (Table 3).
The number of metastases as a selection criterion was
investigated. For 85.6% of the surveyed surgeons there is no
maximum number of metastases that can be considered for
removal, with any number being acceptable provided that
complete resection is considered achievable. On the contrary,
the surveyed cohort is divided as to the maximum number of
repeat metastasectomies: 52.7% declare having no limit as
TABLE 2. Indications According to the Histology of the
Primary Tumor
Yes No
Response
Count
“For which kind of primary tumors do you perform lung
metastasectomy?”
Colon cancer 99.3% (141) 0.7% (1) 142
Kidney cancer 98.6% (137) 1.4% (2) 139
Soft tissue sarcomas 95.6% (131) 4.4% (6) 137
Osteosarcomas 92% (127) 8% (11) 138
Germ cell tumors 89.4% (110) 10.6% (13) 123
Breast cancer 84.3% (107) 15.7% (20) 127
Melanoma 84% (105) 16% (20) 125
Head and neck tumors 83.1% (98) 16.9% (20) 118
Endometrial cancer 70.6% (77) 29.4% (32) 109
Lung cancer 69.4% (86) 30.6% (38) 124
Cervix cancer 66.1% (72) 33.9% (37) 109
Ovarian cancer 57.9% (62) 42.1% (45) 107
TABLE 3. Perceived Contraindications to Lung Metastasectomy
Absolute
Contraindication
Relative
Contraindication
Not a
Contraindication
“Do you consider any of the following as contraindications to pulmonary metastasectomy?”
Multiple (1) metastases 0 (0%) 22 (15%) 124 (85%)
Bilateral pulmonary metastases 2 (1%) 24 (16%) 120 (82%)
Previous pulmonary metastases 1 (1%) 36 (25%) 109 (75%)
Synchronous pulmonary metastases (found at the time
of diagnosis of primary malignancy)
4 (3%) 69 (47%) 73 (50%)
Disease free interval shorter than 12 mo 2 (1%) 51 (35%) 93 (64%)
Concurrent metastases in a nonpulmonary site 49 (34%) 84 (58%) 13 (9%)
Poor performance status (Karnofsky score 50%) 56 (38%) 87 (60%) 3 (2%)
Poor lung function (FEV1 or DLCO 40% of predicted) 37 (25%) 100 (68%) 9 (6%)
Clinically positive mediastinal lymphadenopathy 25 (17%) 93 (64%) 28 (19%)
Pathologically positive (mediastinoscopy) mediastinal
lymphadenopathy
94 (64%) 46 (32%) 6 (4%)
Unresectable primary malignancy 134 (92%) 10 (7%) 2 (1%)
Metastasis/metastases requiring pneumonectomy
for complete resection
34 (23%) 93 (64%) 19 (13%)
Age 70 1 (1%) 56 (38%) 89 (61%)
Age 80 27 (18%) 77 (53%) 42 (29%)
BMI 35 kg/m2 2 (1%) 90 (62%) 31 (21%)
BMI 15 kg/m2 25 (17%) 90 (62%) 31 (21%)
Complete resection of pulmonary metastasis/metastases is
not possible as evidenced on preoperative investigations
108 (74%) 35 (24%) 3 (2%)
BMI, body mass index; DLCO, diffusing capacity of the lung for carbon monoxide.
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long as complete resection is possible, whereas the remaining
47.3% mostly set a limit to redo resections between 2 and 5.
Completeness of resection represents an absolute con-
traindication to metastasectomy for 74% of the responders
and a relative contraindication for 24%.
Surgical Approach
Palpation of the lung is deemed mandatory by 65.1% of
the responding surgeons, whereas 34.9% consider it not
always necessary. The surveyed cohort is similarly segre-
gated with regard to the use of the video-assisted thoraco-
scopic surgery/thoracoscopic (without complete palpation)
approach: 60.3% consider it a valuable option only with
diagnostic intent, while 39.7% recommend it also with the
aim at obtaining complete resection in selected cases. Among
the supporters of the open approach, different types of tho-
racotomy are used for resection clinically unilateral disease;
sternotomy is not popular (Table 4). In the case of bilateral
disease, bilateral staged thoracotomy is the favored approach
(66.2%), followed by sternotomy (26.9%) and bilateral se-
quential (one stage) thoracotomy (19.3%); bilateral thoracos-
copy (either staged or sequential) is performed by 20%.
Notably, for the 83.6% of the surveyed thoracic surgeons, the
surgical approach is not always the same, but tailored for
each case according to: performance status and lung function
(84%), age of the patient (56%), type of primary tumor
(41%), location (98%), and number (88%) of metastases.
In the case of staged operations for bilateral disease, 3
to 4 weeks is the time interval advocated by 3⁄4 of the
surveyed surgeons (with a range of 2 days to 6 weeks).
Extent of Resection and Surgical Technique
Wedge resection is definitely the most common way to
resect metastases (89% of respondents). Precision excision is
advocated by 17.8%, while anatomic segmentectomy (4.8%)
and lobectomy (2.1%) are preferred by a relative few. The
need for pneumonectomy to achieve complete resection is
considered a relative contraindication for 2 of 3 of the
respondents, and an absolute contraindication for a further
23%. The resection is carried out by means of a surgical
stapler (82.2%), electrocautery (32.2%), direct suture
(24.7%), laser (12.3%). Other instruments (harmonic scalpel,
Ligasure, etc) are rarely used.
Lymph Node Assessment and Dissection
The presence of clinically positive lymphadenopathy is
believed to be a relative contraindication to pulmonary me-
tastasectomy by 64% (Table 3), while biopsy proven or
pathologically positive mediastinal nodes constitute an abso-
lute (64%) or relative (32%) contraindication for most of the
observed population. Nevertheless, a systematic assessment
of mediastinal nodes prior to lung metastasectomy is appar-
ently an uncommon practice (Table 5): most of the respond-
ers rarely (43.8%) or never (24%) perform mediastinoscopy,
while another 28.8% state this is done only “sometimes,” and
usually because of increased suspicion raised by preoperative
imaging tests. Only 3.4% of responders consistently verify
mediastinal lymph nodes by mediastinoscopy (2% usually,
1.4% always) before selecting a patient for surgical resection.
At the time of pulmonary metastasectomy, roughly half
(55.5%) of the responding surgeons perform mediastinal
lymph nodal sampling, while 13% perform a complete me-
diastinal lymphadenectomy. One surgeon out of 3 (32.2%)
performs no lymph node biopsy whatsoever.
Follow-Up
Just over half of the responding surgeons always
(22.6%) or usually (29.5%) personally carry out the fol-
low-up of their metastasectomy patients, with the rest of
cohort referring the patients to an oncologist for continued
follow-up. Those surgeons who do follow-up their patients
generally use either helical or conventional CT scan (100% of
the 110 who answered this question), PET scan (40/110,
36.4%) and tumor markers (75/110, 68.2%). The most pop-
TABLE 4. Surgical Approach
n (%)
“Which is your preferred approach for clinical unilateral disease?”
Anterolateral thoracotomy 53 (36.3)
Thoracoscopy (VATS) 42 (28.8)
Posterior muscle sparing thoracotomy 38 (26)
Posterolateral thoracotomy 33 (22.6)
Horizontal axillary thoracotomy 15 (10.3)
Vertical axillary thoracotomy 10 (6.9)
Sternotomy 2 (1.4)
Other 7 (4.8)
“Which is your preferred approach for clinical bilateral disease?”
Bilateral staged thoracotomy 96 (66.2)
Sternotomy (one stage) 39 (26.9)
Bilateral sequential thoracotomy (one stage) 28 (19.3)
Bilateral staged thoracoscopy 18 (12.4)
Bilateral thoracoscopic (one stage) 11 (7.6)
Clamshell (one stage) 11 (7.6)
Other 3 (2.1)
VATS, video-assisted thoracoscopic surgery.
TABLE 5. Preoperative and Intraoperative Mediastinal
Nodes Assessment
n (%)
“Do you perform cervical mediastinoscopy with lymph node biopsy prior
to metastasectomy?”
Always 2 (1.4)
Usually 3 (2.1)
Sometimes 42 (28.8)
Rarely 64 (43.8)
Never 35 (24)
“At the time of pulmonary metastasectomy, which of the following do
you routinely perform?”
Mediastinal lymph nodal sampling 81 (55.5)
No lymph nodal sampling/dissection 47 (32.2)
Complete mediastinal lymphadenectomy 19 (13)
Prethoracotomy cervical mediastinoscopy 6 (4.1)
Prethoracotomy TEMLA 2 (1.4)
TEMLA: Transcervical Extended Mediastinal Lymphadenectomy.
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ular time interval between follow-up CT imaging is between
6 and 12 months.
DISCUSSION
Lung metastasectomy is widely performed in the treat-
ment of a variety of primary solid tumors. All surgeons
responding to this survey perform pulmonary metastasecto-
mies, though, in most cases, it accounts for a minor part of
their surgical volume. A certain bias is inherent in this aspect
of the study as those who do not perform pulmonary metas-
tasectomy may be much less likely to participate in such a
survey.
It is likely that this survey is biased towards those with
a greater commitment to performing metastasectomy.
The largest series to date regarding the role of pulmo-
nary metastasectomy is provided by the report from the
International Registry of Lung Metastases (IRLM).4 It should
be noted that drawing inferences about the cause and effect of
treatment from case series has a number of statistical pitfalls.5
Nevertheless in so far as the series allows us to identify which
patients among those operated have longer and shorter sur-
vival time, the evidence from the register is reliable and
consistent with smaller series. The IRLM defined four major
prognostic indicators for long-term survival of patients fol-
lowing lung metastasectomy: completeness of resection, dis-
ease free interval, number of metastases, and primary tumor
histology. It is accepted that implementation of selection on
the basis of these criteria would lead to biases in the long term
results of surgical resection because of selecting biologically
favorable tumors.3 Papers reporting the predictive power of
these factors often stress that the metastasectomy seems to be
effective in selected cases and advocate that these factors should
be the basis of selection. Contrary to this advice we note that half
of the responders will operate when there is no “disease free
interval,” 85% operated on multiple metastases and most do not
exclude patients on the basis of the histologic type.
Other numerous and varied issues that could not be
adequately addressed by the IRLM in 1997 and would require
prospective trials (such as reliability of imaging tools, open
versus thoracoscopic approach, need for bilateral exploration
in cases of clinically unilateral disease) remain areas of clinical
controversy as evidenced by the lack of consensus in practice
among the surveyed surgeons6,7 10 years following this report.
There is a clear perception among the surveyed sur-
geons that there is merit in discussing the metastasectomy
cases within multidisciplinary meetings. One of the argu-
ments to pursue the surgical treatment of lung metastases is
the lack of better systemic alternative. As advances in sys-
temic treatment progress, the selection criteria for surgical
resection of metastases change as well, as has happened in the
last decades for lung metastases from breast cancer or germ
cell tumors. Moreover, chemotherapy can be considered as a
“time window” to test the biologic aggressiveness of the tumor
in doubtful cases. When widespread progression of metastases
occurs during chemotherapy, it is generally accepted that the
disease will progress regardless of surgery. This is clearly
perceived by the surgeons surveyed in this study but the
observation cannot distinguish between benefit totally attrib-
utable to chemotherapy and an added effect of surgery.
As far as the preoperative assessment is concerned,
imaging plays a major role. Our study population relies
predominantly on CT scanning (either conventional or heli-
cal, depending on local availability), which remains the
standard procedure investigation for evaluating pulmonary
metastases. The use of PET is not as common (less than 50%
of the responders use it). It may simply be less available to
some surgeons. It may improve preoperative staging by
detecting extrapulmonary disease, but because of its insensi-
tivity for nodules below about a centimeter in size, it cur-
rently does not add to CT scan in regard to the definition of
number and location of lung nodules.
Bearing in mind the widely accepted importance of
the completeness of resection, an argument for palpation of
the lung in all cases of metastasectomy has been put
forward. The lack of consensus on this point among our
surveyed cohort of surgeons is in line with the failure of a
recent systematic review6 to define the role of palpation. A
similar dilemma remains regarding the need for bilateral
exploration and palpation of both lungs in case of clinical
unilateral disease.7 These issues, although explored in retro-
spective series, have not been proven in a prospective study
and still present controversy for thoracic surgeons. There was
an attempt to run a trial of the effectiveness of CT scan and
video-assisted thoracoscopic surgery but in 10 of 18 cases
additional malignant lesions were found at thoracotomy and
the study was abandoned.8 Two-thirds of our surveyed pop-
ulation believe palpation of the lung is necessary when
performing lung metastasectomy with curative intent, but 1 of
3 of those surveyed are willing to forego this for the most part
by using thoracoscopy in some circumstances. Nevertheless,
the percentage of surgeons who perform a bilateral explora-
tion (either by sternotomy or bilateral thoracotomy) is quite
low (Table 4). The precise incidence and clinical relevance of
lymph node involvement in patients with lung metastases has
not yet been completely elucidated. The incidence of lymph
node involvement reported in the literature varies from about
14.5%9,10 to 28.6%.11,12 As would be expected these observed
ranges vary by the cell-type of the primary tumor, the vari-
ation in preoperative work-up and lymph node assessment
(sampling versus complete dissection).
This study has some limitations that must be discussed.
Though, of course, it should be noted that the opinion of the
ESTS members responding to the questionnaire may not
necessarily reflect all the ESTS members, the response rate of
29.5% is significant enough to avoid a “nonresponse error.” It
should be considered also that only those who do perform
metastasectomy answered the questionnaire. We therefore do
not have data on how many ESTS Members, if any, do not
perform pulmonary metastasesectomy or the reasons for such
a choice.
Another limitation innate in a survey is that it is not
possible to check in detail all the different aspects of lung
metastasectomy by means of a questionnaire made of closed-
ended questions and meant to be easy, direct and not time-
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consuming for the responder. Nevertheless, it was possible to
sketch some general patterns of the actual clinical practice.
Survey studies rely on “self-report” data, they depend
on how true and accurate the respondents are, so biases due
to the respondents trying to conform consciously or uncon-
sciously to the expectations of those who are studying them
must be kept in mind.
The ESTS LungMetastasectomyWorking Group realizes
that this survey merely provides a time-sensitive perspective of
the patterns of practice in pulmonary metastasectomy. It is,
however, the largest such comprehensive examination of clinical
practice in this field of surgery to date. Clearly, the emergence of
new technologies, be they in imaging or surgical instrumenta-
tion, will cause practices to evolve.
It should be underlined that the findings of this survey do
not serve as a series of recommendations in the field of pulmo-
nary metastasectomy but rather a snapshot of current practice of
surgical treatment of lung metastases. The results of the survey
do emphasize certain areas of current clinical practice where
there is consistency: pulmonary metastasectomy is not war-
ranted in cases where the primary tumor is uncontrolled or
where complete resection of lung metastases is not likely. The
survey also uncovers or confirms areas where considerable
debate remains as evidenced by the wide variability of practice
in such areas as surgical approach and the role of repeat metas-
tasectomy. Going forward with the results of this survey, it may
be possible to foster support for cooperative research projects
within the ESTS or other similar bodies to embark on systematic
research projects in these areas of controversy.
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APPENDIX
APPENDIX. ESTS Lung Metastasectomy Working Group. Questionnaire
1. Do you perform lung metastasectomy in your clinical practice?
Yes
No
2. How many pulmonary metastasectomy cases per year do you personally perform?
3. As a proportion of your clinical volume, pulmonary metastasectomy accounts for approximately what percent of you practice?
0–10%
10–25%
25–50%
50%
4. For which kind of primary tumors do you perform metastasectomy?
Yes No
Colon cancer
Osteosarcomas
Soft tissue sarcomas
Kidney cancer
Melanoma
Germ cell tumors
Hand and neck tumors
Endometrial cancer
Cervix cancer
Ovarian cancer
Lung cancer
Breast cancer
5. Others (please specify)
6. Do you administer preoperative chemotherapy before metastasectomy?
Always
Usually
Sometimes
Never
Decision rests with medical oncologists
7. For which primary histologies listed below do you recommend preoperative chemotherapy before pulmonary metastasectomy?
Always Usually Sometimes Rarely Never
Colon cancer
Osteosarcomas
Soft tissue sarcomas
Kidney cancer
Melanoma
Germ cell tumors
Lung cancer
Breast cancer
Endometrial cancer
Cervix cancer
Ovarian cancer
8. Others (please specify)
9. Do you review pulmonary metastasectomy cases in a multidisciplinary (thoracic surgery, pulmonology, medical oncology, radiation oncology)
meeting?
Always, every case
Usually
Rarely
Never
10. Which imaging studies do you use for diagnosis and planning pulmonary metastasectomy?
Always Usually Sometimes Rarely Never
Conventional CT scan
Helical CT scan
PET scan
(Continued)
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APPENDIX. (Continued)
11. Other diagnostic tools (please describe):
12. Do you perform cervical mediastinoscopy with lymph node biopsy prior to metastasectomy?
Always, every case
Usually
Sometimes
Rarely
Never
13. Do you measure serum tumor markers (according to the primary tumor histology) before metatsasecomy?
Always, every case
Usually
Sometimes
Rarely
Never
14. Do you consider any of the following as contraindications to pulmonary metastasectomy?
Absolute
Contraindication
Relative
Contraindication
Not a
Contraindication
Multiple (more than one) metastases
Bilateral pulmonary metastases
Previous pulmonary metastases
Synchronous pulmonary metastases (found at the time
of diagnosis of primary malignancy
DFI 12 mo
Concurrent metastases in a nonpulmonary site
Poor performance status (Karnofsky score 50%)
Poor lung function (FEV1 or DLCO 40% of predicted)
Clinically positive (mediastinoscopy) mediastinal lymphadenopathy
Pathologically positive (mediastinoscopy) mediastinal lymphadenopathy
Unresectable primary malignancy
Metastasis/metastases requiring pneumonectomy for complete resection
Age 70
Age 80
BMI 35 kg/m2
BMI 15 kg/m2
Complete resection of pulmonary metastasis/metastases is not possible
as evidenced on preoperative investigations
15. Do you have an absolute maximum number of metastases that you will remove at the time of surgery? If yes, what is your maximum limit?
No
Yes
Please specify your maximum limit
16. Do you perform repeat pulmonary metastasectomy? If yes, do you have an absolute maximum number of repeat resections that you would consider
for recurrent pulmonary metastatic disease?
No
Yes
Please specify your maximum limit
17. Do you believe palpation of the lung is necessary in metastasectomy with therapeutic intent?
Always
Sometimes
Never
18. Do you use the VATS/thoracoscopic (without palpation) approach for lung metastases surgery?
For diagnosis only (ex.: indeterminate nodule/nodules)
Also with therapeutic intent (metastasectomy)
19. Which is your preferred approach for clinical unilateral disease?
Posterolateral thoracotomy
Anterolateral thoracotomy
Vertical axillary thoracotomy
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Horizontal axillary thoracotomy
Hemi-clamshell (submammary)
Posterior muscle sparing thoracotomy
Thoracoscopy (VATS)
Sternotomy
Others
20. Which is your preferred approach for clinical bilateral disease?
Bilateral thoracoscopy (one stage)
Bilateral staged thoracoscopy
Sternotomy (one stage)
Clamshell (one stage)
Bilateral sequential thoracotomy (one stage)
Bilateral staged thoracotomy
Others
21. In the case of bilateral staged thoracotomy/thoracoscopy, what time interval do you advocate/prefer between the 2 operations?
22. Do you use different surgical approaches for metastasectomy based on individual factors?
Yes
No
23. If yes, what might influence your decision?
Yes No
Preoperative performance status and lung function
Age
Type of primary tumor
Location of the metastasis/metastases
Number of the metastases
24. In the case of a solitary peripheral pulmonary metastasis (high probability or proven), which type of resection do you most commonly use?
Local excision
Wedge resection
Segmentectomy
Lobectomy
25. In the case of a solitary peripheral pulmonary metastasis (high probability or proven), which type of resection do you most commonly use?
Local excision
Wedge resection
Segmentectomy
vLobectomy
26. For pulmonary metastasectomy, which of these instruments do you most commonly use?
Electrocautery
Stapler
Laser
Harmonic scalpel
Direct suture
Other
27. At the time of pulmonary metastasectomy, which of the following do you routinely perform?
No lymph nodal sampling/dissection
Mediastinal lymph nodal sampling
Complete mediastinal lymphadenectomy
Prethoracotomy cervical mediastinoscopy
Prethoracotomy TEMLA
28. Feel free to add any comment to the previous question.
29. Do you personally carry out long term follow-up of your pulmonary metastasectomy patients?
Always
Usually
Sometimes
Rarely
Never
(Continued)
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30. If yes, what are your standard investigations?
Conventional CT scan
Helical CT scan
PET scan (positive tumors)
Tumor markers (positive tumors)
31. Feel free to add any comment to the previous question
32. Type of practice
Academic
Public
Private
33. Level of practice
Trainee
Consultant
34. Age (yr)
35. Years in practice
36. Hospital size (number of beds)
37. Unit size (number of beds)
38. Country of practice
39. Feel free to add any comment/consideration on this questionnaire
VATS, video-assisted thoracoscopic surgery; PET, positron emission tomography; CT, computed tomography; BMI, body mass index.
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